LLY Up 28% in 3 Months: Is it the Right Time to Invest in the Stock?
View original at finance.yahoo.comLLY Up 28% in 3 Months: Is it the Right Time to Invest in the Stock? Eli Lilly and Company’s LLY stock has risen 28% in the past three months…
What we drew from this source
The claims Via News extracted from this document. We point to the source; we don't replace it.
Eli Lilly expects data readouts from three phase III studies on retatrutide for treating obesity in the second half of 2026
80% confidenceMounjaro and Zepbound are expected to continue to see strong demand in 2026
80% confidenceStructure Therapeutics expects to initiate late-stage program of aleniglipron in obesity around mid-2026
80% confidenceThe obesity market is huge and multiple players can co-exist
80% confidenceNovo Nordisk expects to launch the Wegovy pill in early January 2026
80% confidenceEli Lilly plans to file regulatory applications for orforglipron in type II diabetes in the first half of 2026
80% confidenceDespite NVO having the lead in the oral obesity market, Lilly may be able to close the gap fast once orforglipron is approved by the FDA in 2026
80% confidenceEli Lilly expects new drugs (Mounjaro, Zepbound, Omvoh, Jaypirca, Ebglyss and Kisunla), along with expanded use of existing drugs, to drive sales growth in 2026
80% confidenceNovo Nordisk will advance next-generation obesity candidate amycretin into late-stage development, both as injection and oral pill, with phase III program planned to initiate during first quarter of 2026
80% confidenceMounjaro and Zepbound account for more than 50% of the company's total revenues
80% confidenceEli Lilly is a great stock to have in one's portfolio, given its significant price appreciation, product and pipeline portfolio, robust growth prospects and bullish analyst sentiment
80% confidenceEli Lilly is a Zacks Rank #1 (Strong Buy) stock
80% confidence